GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
71.13
+7.69 (12.12%)
Jul 30, 2026, 3:52 PM EDT - Market open
GRAIL Revenue
GRAIL had revenue of $40.79M in the quarter ending March 31, 2026, with 28.11% growth. This brings the company's revenue in the last twelve months to $156.12M, up 19.44% year-over-year. In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth.
Revenue (ttm)
$156.12M
Revenue Growth
+19.44%
P/S Ratio
19.00
Revenue / Employee
$171,560
Employees
910
Market Cap
3.05B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 147.17M | 21.58M | 17.18% |
| Dec 31, 2024 | 125.60M | 32.49M | 34.90% |
| Dec 31, 2023 | 93.11M | 37.56M | 67.61% |
| Jan 1, 2023 | 55.55M | 40.94M | 280.17% |
| Jan 2, 2022 | 14.61M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.14B |
| Sotera Health Company | 1.19B |
| NeoGenomics | 766.30M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Twist Bioscience | 409.48M |
| BillionToOne | 354.54M |
GRAL News
- 5 hours ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL - PRNewsWire
- 23 hours ago - GRAIL to Announce Second Quarter 2026 Financial Results - PRNewsWire
- 6 days ago - $GRAL Fraud Notification: GRAIL, Inc. Sued for Fraud Over Misrepresentations about its Trial Results – Investors Notified to Contact BFA Law - GlobeNewsWire
- 14 days ago - Grail’s Gallery cancer detection test adopted by Priority Health - TheFly
- 14 days ago - Priority Health Collaborates With GRAIL as the First Michigan Health Plan to Offer the Galleri® Multi-Cancer Early Detection Blood Test to Employer Plans - PRNewsWire
- 15 days ago - Grail price target raised to $88 from $69 at TD Cowen - TheFly
- 15 days ago - Grail price target raised to $65 from $58 at Mizuho - TheFly
- 16 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of August 4, 2026 in Grail, Inc. Lawsuit - GRAL - GlobeNewsWire